Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact
- 18 November 2025
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (2) , 142-148
Abstract
Late Immune Effector Cell-Associated HematoToxicity (ICAHT) is a recognized complication following CAR T therapy, yet their incidence and clinical consequences remain poorly defined. We assessed early and late hematotoxicity in 290 patients with large B-cell lymphoma receiving CAR T therapy. Early ICAHT ( ≤ 30 days post-infusion) occurred in 78% of patients (grade 1: 22%, grade 2: 26%, grade 3: 22%, grade 4: 8.1%). Cumulative incidence of late ICAHT ( > 30 days post-infusion) by day 100 was 45% (95% CI 39–51) for any grade, 40% (95% CI 34-46) for grade≥2, 22% (95% CI 17–27) for grade ≥3, and 7.2% (95% CI 4.4–11) for grade 4. Cumulative incidences of late moderate-severe thrombocytopenia ( < 50 × 103/μL) and anemia ( < 8 g/dL) at day 100 were 20% (95% CI 15–25) and 14% (95% CI 10-19), respectively. Early severe ICAHT (grade ≥3) was independently associated with late severe ICAHT (p < 0.001), late severe thrombocytopenia (p < 0.001), and late moderate-severe anemia (p = 0.037). Late severe ICAHT was associated with an increased hazard of late infections (HR 2.85 [95% CI 1.18–6.88], p = 0.032). These findings highlight late hematologic toxicity as a frequent and clinically relevant complication of CAR T therapy. Incorporating ICAHT grading into post-infusion monitoring may inform preventive strategies to mitigate long-term complications.Keywords
Funding Information
- Dr. Magdalena Corona’s work was supported by a grant from the Alfonso Martin Escudero Foundation
- Dr. Alejandro Luna’s work was supported by an FEHH/Gilead grant
- Comedy vs. Cancer, Long Island Sound, Chapter, Swim Across America
This publication has 45 references indexed in Scilit:
- Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementThe Lancet Haematology, 2024
- Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphomaBlood Cancer Journal, 2023
- Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paperInfection, 2020
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and managementBlood Reviews, 2019
- Toxicities of CD19 CAR‐T cell immunotherapyAmerican Journal of Hematology, 2019
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2019
- EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysisThe Lancet Haematology, 2017